Holen Sie sich die Stockscreener-App
2.40
5.73%
0.13
Handel nachbörslich:
2.40
Schlusskurs vom Vortag:
$2.27
Offen:
$2.3
24-Stunden-Volumen:
720.49K
Relative Volume:
0.95
Marktkapitalisierung:
$83.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-28.85M
KGV:
-1.7117
EPS:
-1.4021
Netto-Cashflow:
$-25.62M
1W Leistung:
+30.43%
1M Leistung:
+2.13%
6M Leistung:
+20.60%
1J Leistung:
+66.67%
1-Tages-Spanne:
$2.20
$2.42
1-Wochen-Bereich:
$1.86
$2.42
52-Wochen-Spanne:
$1.44
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.40 | 78.65M | 0 | -28.85M | -25.62M | -1.4021 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results - MyChesCo
Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research - TMX Newsfile
ANVS Earnings History & Surprises | EPS & Revenue Results | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Bio | DEF 14A: Definitive information statements - Moomoo
Annovis Bio (ANVS) seeks approval to expand 2019 equity incentive plan at 2026 meeting - Stock Titan
Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN
Annovis Bio reports positive cognition data in early Alzheimer’s trial - Investing.com UK
Annovis Bio reports positive cognition data in early Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Bio reports positive cognition results in early Alzheimer’s trial By Investing.com - Investing.com Nigeria
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio - The Manila Times
Annovis Bio reports positive cognition results in early Alzheimer’s trial - Investing.com
Annovis drug showed cognition gains in early AD; 80% enrolled in Phase 3 - Stock Titan
Annovis Bio, Inc. (NYSE:ANVS) Sees Significant Increase in Short Interest - MarketBeat
Annovis Bio Announces Transfer of Listing to the New York Stock Exchange - TMX Newsfile
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease - TMX Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022) - TMX Newsfile
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences - TMX Newsfile
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics - TMX Newsfile
Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference - TMX Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 - TMX Newsfile
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging - TMX Newsfile
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference - TMX Newsfile
Traders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS) - MarketBeat
Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo
Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com Australia
Annovis Bio highlights buntanetap development in published article - MSN
Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter
Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com
A $10M cash boost puts Annovis on track for an Alzheimer’s drug filing - Stock Titan
Annovis Closes $10 Million Offering, Extending Cash Runway - GlobeNewswire
Annovis Bio Announces $10 Million Underwritten Offering to Advance Alzheimer’s and Parkinson’s Drug Development - Minichart
Annovis Bio Prices Registered Direct Offering to Fund Trials - TipRanks
Annovis Bio Secures ~$10 Million Underwritten Registered Direct Offering With Canaccord Genuity - TradingView
Weekly Trades: Will Annovis Bio Inc. benefit from rising consumer demand2026 Market Trends & Safe Capital Preservation Plans - baoquankhu1.vn
Quarterly Risk: Will Annovis Bio Inc stock hit new highs in YEAR2026 Growth vs Value & Weekly Breakout Watchlists - baoquankhu1.vn
Annovis Bio prices $10M stock offering at $1.90 per share - Investing.com Australia
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Annovis Bio (ANVS) raises ~$10M via 5.26M-share registered direct offering - Stock Titan
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - Bitget
Form 424B5 Annovis Bio, Inc. - StreetInsider
Annovis Bio stock tumbles 26% on dilutive equity offering By Investing.com - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Annovis Bio stock tumbles 26% on dilutive equity offering - Investing.com
Anovis Bio Inc stock: $10M raise amid Phase 3 push – what it means for you - AD HOC NEWS
Annovis Bio prices $10M stock offering at $1.90 per share By Investing.com - Investing.com South Africa
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):